On September 4, 2018, leaders of the Avicenna Alliance—Association for Predictive Medicine spoke at the European Parliament in Brussels about the central role played by in silico healthcare in accelerating innovations in medical devices and treatments. While the U.S. FDA has begun accepting simulation data as part of the trial and approval process, Europe is lagging in this regard. Senior representatives from the FDA, ANSYS, Medtronic, CIPLA, EFGCP and RPP discussed how the EU can incorporate in silico medicine to assume a leading role in a globally harmonized and regulated healthcare environment.
See highlights from Brussels and representatives discuss in silico applications in this video: